Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 6/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.30 |
| ▸ | CDK1 | P06493 | 2/20 | 0.30 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.30 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.30 |
| ▸ | KDM6B | O15054 | 1/20 | 0.30 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23133117 | 0.88 | CYP1A2 (0.41) | CYP1A2CYP3A4CYP2D6ALDH1A1CYP2C19 | |
| SCHEMBL23133119 | 0.75 | AOC1 (0.42) | KDM6BKDM4C | |
| SCHEMBL23133038 | 0.75 | AOC1 (0.42) | KDM6BKDM4C | |
| SCHEMBL23133240 | 0.75 | HSP90AA1 (0.42) | ALDH1A1HSD17B10TDP1TSHRKDM4E | |
| SCHEMBL23133104 | 0.73 | TSHR (0.34) | CYP1A2TSHR | |
| SCHEMBL21527439 | 0.73 | CYP1A2 (0.37) | CYP1A2ALDH1A1TSHR | |
| SCHEMBL23133094 | 0.71 | UTS2R (0.38) | CYP1A2CYP3A4CYP2D6ALDH1A1TSHR | |
| SCHEMBL23133072 | 0.71 | ALDH1A1 (0.40) | CYP1A2CYP3A4CYP2D6ALDH1A1HSD17B10 | |
| SCHEMBL23133248 | 0.69 | TSHR (0.34) | CYP1A2TSHR | |
| SCHEMBL21267252 | 0.68 | MAPT (0.39) | CYP1A2ALDH1A1CYP2C19HSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230000773-A1 | NOVEL HEADGROUP LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2023-01-05 | — | — | US | disclosed |
| WO-2021055849-A1 | HEADGROUP LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX, INC. (US) | 2021-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230000773-A1 | NOVEL HEADGROUP LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PEBP1, PLTP | CYP1A2 4879/4885CYP3A4 4867/4885CYP2D6 4823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.